Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)

Completed

Conditions: Haemophilia B With Inhibitors
Haemophilia A
Haemophilia A With Inhibitors
Haemophilia B

Interventions: Other: No treatment given

First Posted Date: 2018-11-15

Last Posted Date: 2021-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 231

Registration Number: NCT03741881

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin icodec

First Posted Date: 2018-10-30

Last Posted Date: 2024-07-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 58

Registration Number: NCT03723785

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Faster Aspart 200 U/mL
Drug: Faster aspart 100 U/mL

First Posted Date: 2018-10-30

Last Posted Date: 2020-03-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT03723759

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Insulin icodec
Drug: IGlar U100

First Posted Date: 2018-10-30

Last Posted Date: 2024-02-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 66

Registration Number: NCT03723772

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Phase 1

Completed

Conditions: Obesity and Overweight

Interventions: Drug: NNC0165-1875
Drug: Placebo (NNC0165-1875)
Drug: Semaglutide

First Posted Date: 2018-10-16

Last Posted Date: 2019-09-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 88

Registration Number: NCT03707990

Locations: 🇺🇸
Novo Nordisk Investigational Site, Tempe, Arizona, United States

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Phase 3

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Placebo (Semaglutide)
Drug: Semaglutide

First Posted Date: 2018-10-03

Last Posted Date: 2023-07-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 304

Registration Number: NCT03693430

Locations: 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

Conditions: Haemophilia B

Interventions: Drug: Nonacog beta pegol

First Posted Date: 2018-10-01

Last Posted Date: 2024-02-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 10

Registration Number: NCT03690336

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Insulin aspart
Drug: Insulin glargine U100

First Posted Date: 2018-09-28

Last Posted Date: 2022-11-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2274

Registration Number: NCT03689374

Locations: 🇹🇷
Novo Nordisk Investigational Site, Trabzon, Turkey

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec
Drug: Insulin glargine

First Posted Date: 2018-09-27

Last Posted Date: 2021-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 498

Registration Number: NCT03687827

Locations: 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa

A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec

First Posted Date: 2018-09-18

Last Posted Date: 2019-12-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 662

Registration Number: NCT03674866

Locations: 🇨🇦
Novo Nordisk Investigational Site, Terrebonne, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy